Effect of multiple intravenous injections of butaphosphan and cyanocobalamin on the metabolism of periparturient dairy cows

Abstract

Numerous adjunct therapeutic agents have been investigated for the treatment or control of fat mobilization syndrome in periparturient dairy cows. The aim of this study was to determine the effects of multiple i.v. injections of 10% butaphosphan and 0.005% cyanocobalamin combination (Catosal, Bayer Animal Health, Leverkusen, Germany) between 1 and 2 wk antepartum (a.p.) on the metabolism and health of dairy cows. Forty-five late-gestation Holstein-Friesian cows (second pregnancy) were allocated randomly to 1 of 3 groups with 15 cows/group: group C6 (6 daily i.v. injections of butaphosphan at 10 mg/kg of body weight (BW) and cyanocobalamin at 5 microg/kg of BW in the last 2 wk of gestation); group C3 (3 daily i.v. injections of butaphosphan at 10 mg/kg of BW and cyanocobalamin at 5 microg/kg of BW in the last week of gestation); and group C0 (equivolume daily i.v. injections of 0.9% NaCl solution). Serum biochemical analysis was performed on jugular venous blood samples that were periodically obtained a.p. and postpartum (p.p.). Health status and milk production were monitored p.p. Serum cyanocobalamin concentration increased in groups C6 and C3 p.p. Multiple daily i.v. injections of Catosal before parturition increased p.p. glucose availability, as evaluated by p.p. serum glucose concentration, and decreased peripheral fat mobilization and ketone body formation, as evaluated by p.p. serum nonesterified fatty acid and beta-OH butyrate concentrations. The number of puerperal infections in the first 5 d after calving was decreased in group C6, relative to group C0. We conclude that multiple injections of Catosal during the close-up period have a beneficial effect on the metabolism of periparturient dairy cows. Our results are consistent with the hypothesis that high-producing dairy cows in early lactation may have a relative or actual deficiency of cyanocobalamin.

Effect of butaphosphan and cyanocobalamin on postpartum metabolism and milk production in dairy cows

“…Although several studies had shown the positive effect of butaphosphan in reducing NEB intensity in high-producing dairy cows during the transition period (Furll et al, 2010;Rollin et al, 2010), its mode of action is not clear yet. What is known about the pharmacokinetics of this molecule is that it is rapidly eliminated from the organism after i.v.…”

“…Some studies have indicated (Furll et al, 2010;Rollin et al, 2010) that the injection of butaphosphan (2 to 8 g/cow) and cyanocobalamin (1 to 4mg/cow) in dairy cows, can reduce NEB intensity in a dose-dependent fashion with at least three injections of 2 g of butaphosphan and 1 mg of cyanocobalamin. Our results indicate that the use of 1 g of butaphosphan/cow, that is, half of the minimum dose used in other studies, is still able to induce positive effects on NEB and milk production.…”

“…Another study also demonstrated that BTPC improved the energetic status of dairy cows during the peripartum period based on concentration of glucose, NEFA, BHB and cholesterol (Furll et al, 2010).…”

“…Overall, current treatments had limited success, and more research is needed. One potential alternative is the use of butaphosphan and cyanocobalamin (BTPC; vitamin B12) injections after calving, which have shown positive effects up to now (Furll et al, 2010;Rollin et al, 2010).…”

Combinação de butafosfan e cianocobalamina no metabolismo da glicose em vacas leiteiras após o parto

“…This also increases the availability of amino acids for gluconeogenesis (Roche et al, 2009, Koster andOpsomer, 2013), promoting the conversion of methylmalonylCoA into succiny-CoA by methylmalonyl-CoA mutase, which is cyanocobalanin-dependent. This is an important route for the entry of propionate into the Krebs Cycle to synthesize energy (Furll et al, 2010). This adaptive mechanism (Roche et al, 2009) could be observed in the treated animals ( Fig.1) which, after insulin administration, showed a decreased glucose metabolism at the end of the treatment (28 days postpartum) when compared to the beginning (8 days postpartum).…”